Lysergamides, also known as ergoamides [1] [2] [3] or as lysergic acid amides, are amides of lysergic acid (LA). They are ergolines, with some lysergamides being found naturally in ergot as well as other fungi. Lysergamides are notable in containing embedded phenethylamine and tryptamine moieties within their ergoline ring system. [4]
The simplest lysergamides are ergine (lysergic acid amide; LSA) and isoergine (iso-lysergic acid amide; iso-LSA). In terms of pharmacology, the lysergamides include numerous serotonin and dopamine receptor agonists, most notably the psychedelic drug lysergic acid diethylamide (LSD) but also a number of pharmaceutical drugs like ergometrine, methylergometrine, methysergide, and cabergoline. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] Various analogues of LSD, such as the psychedelics ALD-52 (1A-LSD), ETH-LAD, LSZ, and 1P-LSD and the non-hallucinogenic 2-bromo-LSD (BOL-148), have also been developed. Ergopeptines like ergotamine, dihydroergotamine, and bromocriptine are also lysergamides, but with addition of a small peptide moiety at the amide. Close analogues of lysergamides that are not technically lysergamides themselves include lisuride, terguride, bromerguride, and JRT.
Lysergamides were first discovered and described in the 1930s. [18] [19] [20]
Simplified or partial ergolines and lysergamides, such as NDTDI (8,10-seco-LSD), DEMPDHPCA, and N-DEAOP-NMT, are also known. [21] [22] [23]
The dosages, potencies, durations, and effects of lysergamides have been reviewed by Alexander Shulgin. [24] [25] [26] [27] [28] They have also been reviewed by Albert Hofmann, [29] David E. Nichols, [30] and other researchers. [31] [32] [33] [34] [35] [36] [37] [38] [39]
Common name | Code | Dose (mg) | Potency (×LSD) | Duration (h) |
---|---|---|---|---|
Lysergic acid amide (LSA; ergine) | LA-111 | 0.5–6 | ≤0.1 | ~4–10 |
Isolysergic acid amide (iso-LSA; isoergine) | Iso-LA-819 | 2–5 | <0.1 | ~4–10 |
Lysergic acid methylamide | LAM | ~0.5 | ≤0.2 | ? |
Lysergic acid dimethylamide | DAM-57 | 0.5–1.2 | 0.1 | ? |
Lysergic acid ethylamide | LAE-32 | 0.5–1.6 | ≤0.1 | ? |
1-Acetyllysergic acid ethylamide | ALA-10 | ~1.2 | ≤0.1 | ? |
1-Methyllysergic acid ethylamide | MLA-74 | ~2 | 0.05 | ? |
Lysergic acid methylethylamide | LME-54 | ? | ~0.33 | ? |
Lysergic acid diethylamide (LSD) | LSD-25, METH-LAD | 0.05–0.2 | 1 | 8–12 |
Isolysergic acid diethylamide | Iso-LSD | >4 | <0.02 | ? |
l-Lysergic acid diethylamide | l-LSD | >10 | <0.01 | ? |
l-Isolysergic acid diethylamide | l-Iso-LSD | >0.5 | <0.05 | ? |
2,3-Dihydro-LSD | 2,3-DH-LSD | ~0.15–0.4 | ~0.15 | ~8–12 |
9,10-Dihydro-LSD | 9,10-DH-LSD | >2.5 | <0.02 | ? |
10-Hydroxy-9,10-dihydro-LSD | Lumi-LSD | ? | <0.01 | ? |
2-Bromo-LSD | BOL-148 | >1 (≥6–20) | <0.1 (≤0.005–0.02) | ? |
2-Iodo-LSD | IOL | ? | ? | ? |
2-Oxo-LSD (2-oxy-LSD) | – | >0.3 | ? | ? |
1-Acetyl-LSD | ALD-52 | 0.1–0.2 | 1 | ? |
1-Methyl-LSD | MLD-41 | 0.2–0.3 | 0.3 | ? |
1-Hydroxymethyl-LSD | OML-632 | ? | ~0.7 | ? |
1-Methyl-2-bromo-LSD | MBL-61, MOB-61 | >10 | <0.01 | ? |
1-Methyl-2-iodo-LSD | MIL | ? | ? | ? |
Lysergic acid propylamide | LAP | >0.5 | <0.2 | ? |
Lysergic acid methylpropylamide | LMP-55, LAMPA | >0.1 | <1 | ? |
Lysergic acid ethylpropylamide | LEP-57 | ? | ~0.33 | ? |
Lysergic acid dipropylamide | DPL | >1 | <0.1 | ? |
Lysergic acid dibutylamide | LBB-66 | ? | 0 | ? |
Lysergic acid diallylamide | DAL | >1 | <0.1 | ? |
Ergonovine (ergometrine)a | – | 5–10 | ≤0.01 | ? |
Methylergonovine (methylergometrine)b | – | 2 | 0.05 | ? |
Methysergide c | UML-491 | 4–8 | 0.02 | ? |
Lysergic acid piperidide | LA-Pip | ? | ? | ? |
Lysergic acid pyrrolidide | LPD-824 | ~0.8 | 0.05–0.1 | ? |
Lysergic acid pyrrolinide | LPN | ? | ? | ? |
1-Methyllysergic acid pyrrolidide | MPD-75 | >1.6 | ≤0.1 | ? |
Lysergic acid morpholide | LSM-775, SLM | 0.3–0.6 | 0.1–0.3 | ? |
Lysergic acid 2,4-dimethylazetidide | LA-SS-Az, LSZ | 0.1–0.3 | 0.5 | ? |
Nor-LSD (6-nor-LSD) | H-LAD | >0.5 | <0.2 | ? |
6-Ethyl-nor-LSD | ETH-LAD | 0.04–0.15 | 2 | 8–12 |
6-Propyl-nor-LSD | PRO-LAD | 0.08–0.2 | 1 | 6–8 |
6-Allyl-nor-LSD | AL-LAD, ALLY-LAD | 0.05–0.16 | 1 | 6–8 |
6-n-Butyl-nor-LSD | BU-LAD | ≥0.4–0.5 | <0.3 | ? |
6-Propynyl-nor-LSD | PARGY-LAD | 0.16–0.5 | 0.2–0.6 | ? |
6-(β-Phenethyl)-nor-LSD | PHENETH-LAD | >0.35–0.5 | <0.3 | ? |
Footnotes:a = Ergonovine is lysergic acid hydroxyisopropylamide. b = Methylergonovine is lysergic acid hydroxy-sec-butylamide. c = Methysergide is 1-methylmethylergonovine (1-methyllysergic acid hydroxy-sec-butylamide). Refs:Main: [24] [25] [26] [27] [28] [40] [41] [42] [38] [39] [18] [32] [33] [36] [35] [43] Additional: [44] [45] [46] |
The properties of various additional lysergamides, for instance in terms of serotonin antagonism, have also been described. [47]
Lysergamides, such as ergine, isoergine, and ergometrine, were discovered by the early 1930s, [18] [19] [20] and LSD was discovered by 1938 and its hallucinogenic effects in 1943 by Albert Hofmann. [48] [49] Many synthetic lysergamide analogues of LSD, modified at the amide and/or 1 or 2 positions, were first described by Hofmann and colleagues in the mid-to-late 1950s. [29] [34] [40] [50] N(6)-Substituted lysergamides were first reported in 1970 and thereafter in the 1970s and 1980s by multiple groups, including Hofmann and colleagues, Yuji Nakahara and Tetsukichi Niwaguchi and colleagues, and David E. Nichols and colleagues. [51] [52] [53] [6] The psychedelic effects of N(6)-substituted lysergamides were reported by Alexander Shulgin in 1986 and thereafter. [54] [37] [25] [28] Additional novel lysergamides modified at the amide, like LA-3Cl-SB and LA-Aziridine, were described by Nichols and Robert Oberlender and colleagues in the late 1980s, [55] [37] [51] while LSZ was described by the same group in 2002. [9]
Structure | Name (synonyms) | CAS # | R1 | R6 | R2 | R3 | Other |
---|---|---|---|---|---|---|---|
![]() | Ergine (lysergic acid amide, lysergamide) | 478-94-4 | H | CH3 | H | H | - |
![]() | Isoergine (isolysergic acid amide, isolysergamide) | 2889-26-1 | H | CH3 | H | H | 8-epi |
![]() | LAM (lysergic acid methylamide) | 50485-06-8 | H | CH3 | CH3 | H | - |
![]() | DAM-57 (lysergic acid dimethylamide) | 4238-84-0 | H | CH3 | CH3 | CH3 | - |
![]() | Ergometrine (ergonovine; lysergic acid propanolamide) | 60-79-7 | H | CH3 | CH(CH3)CH2OH | H | - |
![]() | Propisergide (1-methylergonovine) | 5793-04-4 | CH3 | CH3 | CH(CH3)CH2OH | H | - |
![]() | Ergotamine (an ergopeptine) | 113-15-5 | H | CH3 | -- | C17H18N2O4 | - |
![]() | Methylergometrine (methylergonovine; lysergic acid butanolamide) | 113-42-8 | H | CH3 | CH(CH2CH3)CH2OH | H | - |
![]() | Methysergide (1-methyl-lysergic acid butanolamide) | 361-37-5 | CH3 | CH3 | CH(CH2CH3)CH2OH | H | - |
![]() | Amesergide (9,10-dihydro-11-isopropyllysergic acid cyclohexylamide) | 121588-75-8 | CH(CH3)2 | CH3 | C6H11 | H | - |
![]() | LY-215840 (1-isopropyl-9,10-dihydro-N-(2-hydroxycyclopent-anyl)lysergamide) | 137328-52-0 | CH(CH3)2 | CH3 | C5H8OH | H | - |
![]() | Cabergoline (N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-6-(prop-2-en-1-yl)-9,10-dihydrolysergamide) | 81409-90-7 | H | H2C=CH-CH2 | CONHCH2CH3 | CH2CH2CH2N(CH3)2 | - |
![]() | LAE-32 (lysergic acid ethylamide) | 478-99-9 | H | CH3 | CH2CH3 | H | - |
![]() | LAP (lysergic acid propylamide) | ? | H | CH3 | CH2CH2CH3 | H | - |
![]() | IPLA (lysergic acid isopropylamide; LAiP) | H | CH3 | CH(CH3)2 | H | - | |
![]() | LAtB (lysergic acid tert-butylamide) | H | CH3 | C(CH3)3 | H | - | |
![]() | LAcB (lysergic acid cyclobutylamide) | H | CH3 | (CH2)4 | H | - | |
![]() | Cepentil (lysergic acid cyclopentylamide) | H | CH3 | (CH2)5 | H | - | |
![]() | LSB (lysergic acid 2-butylamide) | 137765-82-3 | H | CH3 | CH(CH3)CH2CH3 | H | - |
![]() | LSP (lysergic acid 3-pentylamide) | H | CH3 | CH(CH2CH3)CH2CH3 | H | - | |
![]() | DPL (lysergic acid dipropylamide) | H | CH3 | CH2CH2CH3 | CH2CH2CH3 | - | |
![]() | DIPLA (lysergic acid diisopropylamide) | H | CH3 | CH(CH3)2 | CH(CH3)2 | - | |
![]() | LBB-66 (lysergic acid dibutylamide) | H | CH3 | CH2CH2CH2CH3 | CH2CH2CH2CH3 | - | |
![]() | DAL (lysergic acid diallylamide) | H | CH3 | H2C=CH-CH2 | H2C=CH-CH2 | - | |
![]() | MIPLA (lysergic acid methylisopropylamide) | 100768-08-9 | H | CH3 | CH(CH3)2 | CH3 | - |
![]() | EIPLA (lysergic acid ethylisopropylamide) | H | CH3 | CH(CH3)2 | CH2CH3 | - | |
![]() | ECPLA (lysergic acid ethylcyclopropylamide) | H | CH3 | C3H5 | CH2CH3 | - | |
![]() | LEO (lysergic acid ethyl-2-hydroxyethylamide) | 65527-58-4 | H | CH3 | CH2CH2OH | CH2CH3 | - |
![]() | LA-MeO [56] | H | CH3 | CH2CH2OCH3 | CH2CH3 | - | |
![]() | ETFELA (lysergic acid N-ethyl-N-(2,2,2-trifluoroethyl)amide) | H | CH3 | CH2CF3 | CH2CH3 | - | |
![]() | WO 2022/008627 Compound 4; TRALA-04 [57] | H | CH3 | CH2CH2F | CH2CH3 | - | |
![]() | WO 2022/226408 Example 29; [58] TRALA-08 | H | CH3 | CH2CH2F | CH2CH2F | - | |
![]() | LA-3Cl-SB (lysergic acid N-(3-chloro-sec-butyl)amide) | H | CH3 | CH(CH3)CClHCH3 | H | - | |
![]() | LME-54 (lysergic acid methylethylamide) | H | CH3 | CH2CH3 | CH3 | - | |
![]() | LAMPA (LMP-55; lysergic acid methylpropylamide) | 40158-98-3 | H | CH3 | CH2CH2CH3 | CH3 | - |
![]() | EPLA (lysergic acid ethylpropylamide; LEP-57) | H | CH2CH3 | CH2CH2CH3 | CH3 | - | |
![]() | LSD (lysergic acid diethylamide; LAD) | 50-37-3 | H | CH3 | CH2CH3 | CH2CH3 | - |
![]() | Iso-LSD | 2126-78-5 | H | CH3 | CH2CH3 | CH2CH3 | 8-epi |
![]() | l-LSD | 3184-49-4 | H | CH3 | CH2CH3 | CH2CH3 | 5,8-epi |
![]() | l-Iso-LSD | H | CH3 | CH2CH3 | CH2CH3 | 5-epi | |
![]() | Nor-LSD (6-nor-LSD) | 35779-43-2 | H | H | CH2CH3 | CH2CH3 | - |
![]() | ETH-LAD (6-ethyl-6-nor-LSD) | 65527-62-0 | H | CH2CH3 | CH2CH3 | CH2CH3 | - |
![]() | PARGY-LAD (6-propynyl-6-nor-LSD) | 2767597-51-1 | H | HC≡C−CH2 | CH2CH3 | CH2CH3 | - |
![]() | AL-LAD (6-allyl-6-nor-LSD) | 65527-61-9 | H | H2C=CH-CH2 | CH2CH3 | CH2CH3 | - |
![]() | PRO-LAD (6-propyl-6-nor-LSD) | 65527-63-1 | H | CH2CH2CH3 | CH2CH3 | CH2CH3 | - |
![]() | IP-LAD (6-isopropyl-6-nor-LSD) | H | CH(CH3)2 | CH2CH3 | CH2CH3 | - | |
![]() | MAL-LAD (METAL-LAD; 6-methallyl-6-nor-LSD) | H | CH2=C(CH3)CH2 | CH2CH3 | CH2CH3 | - | |
![]() | CYP-LAD (TRALA-22; 6-cyclopropyl-6-nor-LSD) | H | C3H5 | CH2CH3 | CH2CH3 | - | |
![]() | CPM-LAD (6-cyclopropylmethyl-6-nor-LSD) | H | CH2C3H5 | CH2CH3 | CH2CH3 | - | |
![]() | BU-LAD (6-butyl-6-nor-LSD) | 96930-87-9 | H | CH2CH2CH2CH3 | CH2CH3 | CH2CH3 | - |
![]() | PHENETH-LAD (6-(phenethyl)-6-nor-LSD) | H | CH2CH2C6H5 | CH2CH3 | CH2CH3 | - | |
![]() | NBOMe-LAD (6-(2-methoxybenzyl)-LAD) | H | CH2C6H4-o-OCH3 | CH2CH3 | CH2CH3 | - | |
![]() | FLUORETH-LAD (FE-LAD; TRALA-15; 6-(2-fluoroethyl)-6-nor-LSD) | H | CH2CH2F | CH2CH3 | CH2CH3 | - | |
![]() | FP-LAD (WO 2022/226408 Example 2; TRALA-16; 6-(3-fluoropropyl)-6-nor-LSD) | H | CH2CH2CH2F | CH2CH3 | CH2CH3 | - | |
![]() | CE-LAD (CHLORETH-LAD; 6-(2-chloroethyl)-6-nor-LSD) | H | CH2CH2Cl | CH2CH3 | CH2CH3 | - | |
![]() | 1F-LSD (1-formyl-LSD) | CH=O | CH3 | CH2CH3 | CH2CH3 | - | |
![]() | ALD-52 (1-acetyl-LSD; 1A-LSD) | 3270-02-8 | COCH3 | CH3 | CH2CH3 | CH2CH3 | - |
![]() | 1P-LSD (1-propionyl-LSD) | 2349358-81-0 | COCH2CH3 | CH3 | CH2CH3 | CH2CH3 | - |
![]() | 1B-LSD (1-butanoyl-LSD) | 2349376-12-9 | COCH2CH2CH3 | CH3 | CH2CH3 | CH2CH3 | - |
![]() | 1V-LSD (1-valeryl-LSD) | CO(CH2)3CH3 | CH3 | CH2CH3 | CH2CH3 | - | |
![]() | 1H-LSD (1-hexanoyl-LSD) | CO(CH2)4CH3 | CH3 | CH2CH3 | CH2CH3 | - | |
![]() | 1DD-LSD (1-dodecanoyl-LSD) | CO(CH2)10CH3 | CH3 | CH2CH3 | CH2CH3 | - | |
![]() | 1cP-LSD (1-cyclopropylmethanoyl-LSD) | COC3H5 | CH3 | CH2CH3 | CH2CH3 | - | |
![]() | 1D-LSD (1-(1,2-dimethylcyclobutane-1-carbonyl)-LSD) | COC4H5(CH3)2 | CH3 | CH2CH3 | CH2CH3 | - | |
![]() | 1-(Furan-2-carbonyl)-LSD (1F-LSD; SYN-L-005) [59] | COC4H3O | CH3 | CH2CH3 | CH2CH3 | - | |
![]() | 1T-LSD (1-(thiophene-2-carbonyl)-LSD) | COC4H3S | CH3 | CH2CH3 | CH2CH3 | - | |
![]() | 1S-LSD (1-(3-(trimethylsilyl)propionyl)-LSD) | CO(CH2)2Si(CH3)3 | CH3 | CH2CH3 | CH2CH3 | - | |
![]() | 1P-AL-LAD (1-propionyl-6-allyl-6-nor-LSD) | COCH2CH3 | H2C=CH-CH2 | CH2CH3 | CH2CH3 | - | |
![]() | 1cP-AL-LAD (1-cyclopropylmethanoyl-6-allyl-6-nor-LSD) | COC3H5 | H2C=CH-CH2 | CH2CH3 | CH2CH3 | - | |
![]() | 1T-AL-LAD (1-(2-thienoyl)-6-allyl-6-nor-LSD) [60] | COC4H3S | H2C=CH-CH2 | CH2CH3 | CH2CH3 | - | |
![]() | 1P-ETH-LAD (1-propionyl-6-ethyl-6-nor-LSD) | COCH2CH3 | CH2CH3 | CH2CH3 | CH2CH3 | - | |
![]() | 1P-MIPLA (1-propionyl-lysergic acid methylisopropylamide) | COCH2CH3 | CH3 | CH(CH3)2 | CH3 | - | |
![]() | 1cP-MIPLA (1-cyclopropionyl-lysergic acid methylisopropylamide) | 3028950-74-2 | COC3H5 | CH3 | CH(CH3)2 | CH3 | - |
![]() | MLD-41 (1-methyl-LSD) | 4238-85-1 | CH3 | CH3 | CH2CH3 | CH2CH3 | - |
![]() | OML-632 (1-hydroxymethyl-LSD) | 114004-70-5 | CH2OH | CH3 | CH2CH3 | CH2CH3 | - |
![]() | LSM-775 (lysergic acid morpholide) | 4314-63-0 | H | CH3 | CH2CH2-O-CH2CH2 | - | |
![]() | LPD-824 (lysergic acid pyrrolidide) | 2385-87-7 | H | CH3 | (CH2)4 | - | |
![]() | MPD-75 (1-methyllysergic acid pyrrolidide) | 7221-79-6 | CH3 | CH3 | (CH2)4 | - | |
![]() | Lysergic acid pyrrolinide | ? | H | CH3 | CH2-CH=CH-CH2 | - | |
![]() | LA-Cispyr | ? | H | CH3 | cis-CH(CH3)-CH2CH2-CH(CH3) | - | |
![]() | LA-Pip (lysergic acid piperidide) | 50485-23-9 | H | CH3 | (CH2)5 | - | |
![]() | LSD-Azepane (lysergic acid azepane) [61] | H | CH3 | (CH2)6 | - | ||
![]() | Lysergic acid 2,4-dimethylazetidide (LA-SS-Az, LSZ) | 470666-31-0 | H | CH3 | CH2(CHCH3)2CH2 | - | |
![]() | WO 2022/008627 Compound 1 [62] | H | CH3 | (CH2)2C(CH2)2O | - | ||
![]() | Lysergic acid-(2,3-dimethylaziridinyl)amide (LA-Aziridine) | ? | H | CH3 | ? | - | |
![]() | 2-Bromo-LSD (BOL-148; bromolysergide) | 478-84-2 | H | CH3 | CH2CH3 | CH2CH3 | 2-Br |
![]() | 2-Iodo-LSD (IOL) | 3712-25-2 | H | CH3 | CH2CH3 | CH2CH3 | 2-I |
![]() | 2-Oxo-LSD (2-oxy-LSD) | ? | H | CH3 | CH2CH3 | CH2CH3 | 2-Oxo |
![]() | 2-Oxo-3-hydroxy-LSD | ? | H | CH3 | CH2CH3 | CH2CH3 | 2-Oxo, 3-OH |
![]() | 1P-BOL-148 (1-propionyl-2-bromo-LSD) | COCH2CH3 | CH3 | CH2CH3 | CH2CH3 | 2-Br | |
![]() | 12-Hydroxy-LSD (12-OH-LSD) | 60573-89-9 | H | CH3 | CH2CH3 | CH2CH3 | 12-OH |
![]() | 12-Methoxy-LSD (12-MeO-LSD) | 50484-99-6 | H | CH3 | CH2CH3 | CH2CH3 | 12-OMe |
![]() | 13-Fluoro-LSD [63] | H | CH3 | CH2CH3 | CH2CH3 | 13-F | |
![]() | 13-Hydroxy-LSD | H | CH3 | CH2CH3 | CH2CH3 | 13-OH | |
![]() | 13-Methoxy-LSD | H | CH3 | CH2CH3 | CH2CH3 | 13-OMe | |
![]() | 14-Hydroxy-LSD | H | CH3 | CH2CH3 | CH2CH3 | 14-OH | |
![]() | 14-Methoxy-LSD | H | CH3 | CH2CH3 | CH2CH3 | 14-OMe |
Structure | Name | Chemical name | CAS # |
---|---|---|---|
![]() | 2,3-Dihydro-LSD (2,3-DH-LSD) | N,N-diethyl-6-methyl-9,10-didehydro-2,3-dihydroergoline-8β-carboxamide | ? |
![]() | 9,10-Dihydro-LSD (9,10-DH-LSD) | (10ξ)-N,N-diethyl-6-methylergoline-8β-carboxamide | 3031-47-8 |
![]() | Bromerguride (2-bromolisuride) | 1,1-diethyl-3-(2-bromo-9,10-didehydro-6-methyl-8α-ergolinyl)urea | 83455-48-5 |
![]() | Descarboxylysergic acid | 6-methyl-9,10-didehydroergoline | 51867-17-5 |
![]() | Disulergine | N,N-dimethyl-N'-(6-methylergoline-8α-yl)sulfamide | 59032-40-5 |
![]() | Dosergoside | N-((1S,2R,3E)-2-hydroxy-1-(hydroxymethyl)-3-heptadecenyl)-6-methylergoline-8β-carboxamide | 87178-42-5 |
![]() | Ergoline | (6aR)-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline | 478-88-6 |
![]() | Etisulergine | N,N-diethyl-N'-(6-methylergolin-8α-yl)sulfamide | 64795-23-9 |
![]() | GYKI-32887 | 8-((N-2-azidoethyl-N-methylsulfonylamino)methyl)-6-methylergol-8-ene | 78463-86-2 |
![]() | JRT | (7S)-N,N-diethyl-6-methyl-6,9-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(15),2,10,12(16),13-pentaene-4-carboxamide | ? |
![]() | Lumi-LSD (10-hydroxy-9,10-dihydro-LSD) | N,N-diethyl-10-hydroxy-6-methylergoline-8β-carboxamide | |
![]() | Lysergine | 9,10-didehydro-6,8β-dimethylergoline | 519-10-8 |
![]() | Lysergol | (6-methyl-9,10-didehydroergolin-8β-yl)methanol | 1413-67-8 |
![]() | Lysergic acid | 6-methyl-9,10-didehydroergoline-8β-carboxylic acid | 82-58-6 |
![]() | Lergotrile | 2-chloro-6-methylergoline-8β-acetonitrile | 36945-03-6 |
![]() | Lisuride | 1,1-diethyl-3-(6-methyl-9,10-didehydroergolin-8α-yl)urea | 18016-80-3 |
![]() | Proterguride (6-propyl-9,10-dihydrolisuride) | 1,1-diethyl-3-(6-n-propyl-8α-ergolinyl)urea | 77650-95-4 |
![]() | Terguride (9,10-dihydrolisuride) | N,N-diethyl-N'-[(8α)-6-methylergolin-8-yl]urea | 37686-84-3 |
There are three main ergot alkaloid classes, clavines, ergoamides (lysergamides), and ergopeptides, with 3 belonging to the ergoamide class." 2.5 Lysergic acid and LSD, p. 6970
The ergot alkaloids are broadly classified into three groups—the clavines, ergoamides, and the ergopeptines, all of which are distinguished by the different modifications appended to the core ergoline structure. [...] Results and discussion / Biosynthetic resolution of the ergot alkaloid pathway
Embedded in the structures of the ergot alkaloids are conformationally-restricted variants of the phenethylamine pharmacophores of both dopamine and related biogenic amines as well as that of serotonin.
{{cite journal}}
: CS1 maint: DOI inactive as of July 2025 (link)Table 4.3.—Comparative Hallucinogenic Potencies in Man of Derivatives of D-Lysergic Acid. [...]
The largest number of structural analogs of LSD that have been prepared involve the opening of one or more of the rings of the parent lysergic acid system. The compounds with the piperidine ring (ring D) opened [see (I)] are encountered as natural products in the several Convolvulaceae discussed in Section II,B on ololiuqui. The opening of ring C (by cleavage of the 10-11 bond to the indole "4 position") results in a series of N-α-disubstituted tryptamines. Additionally, analogs are known with the indolic nitrogen replaced with sulfur (benzothiophenes) and with an aliphatic chain (tetralins). A recent review covers this chemistry (Campaigne and Knapp, 1971), but there is apparently no human psychopharmacology as yet known.
The second major location of variations in the structure of LSD has been in the nature of the alkyl groups on the amide nitrogen atom. Some of these are Sandoz syntheses, some are from other research groups, and a few of them are found in nature. Some of these have been studied in man, and some have not. A few of the original clutch of Sandoz compounds have both 1-substituents and amide alkyl (R) group variations: [...]
Table 1. Human psychotomimetic potencies of LSD analogs. [...]
Table 2. Psychotomimetic activity and some pharmacodynamic effects of structural analogues of LSD [...]
Table 2. Relative potency values for lysergic acid amides. [...]
Table I – Structure and Several Biological Activities of Lysergates [...]
Table I – Quantum Chemical Data on Lysergamide Derivatives
Table 4 Human potency data for selected hallucinogens. [...]
Ergine, or lysergic acid amide (LSA), is an alkaloid of the ergoline family closely related to LSD, found in the seeds of Argyreia nervosa (Hawaiian baby woodrose) and Ipomoea violacea (Morning Glories). Hallucinogenic activity of LSA occurs with 4-10 seeds of Argyreia nervosa or with 150–200 seeds (3–6 g) of Ipomoea violacea: seeds could be crushed or eaten whole, or also drunk as an extract, after soaking in water [42]. The onset of the hallucinatory effects, after ingestion of Hawaiian Baby Woodrose, is from 20 to 40 minutes and their total duration is from 5 to 8 hours: the plateau is reached after 4-6 hours and the return to normality is after 1-2 hours from the plateau. [...] However, as regards to the assumption of the Morning Glory seeds, the onset of the hallucinatory effects is from 30 to 180 minutes and they last for 4 to 10 hours. The users reported that they return to normality after about 24 hours [67].
TABLE XII. Antiserotonin and Hallucinogenic Activities and Hückel's Total MO Energy of LSD and its Analogues [...] Data collected by Kumbar and Siva Sankar,91,92 from ref 70a, 87, 88, and 90; all activities are relative to that of LSD taken as 100.
In 1977 and 1978 Hofmann reported that ergonovine maleate was entheogenic,1 a surprising finding in view of its widespread use in obstetrics (Wasson, Hofmann & Ruck 1978; Hofmann 1977). This report was based on a self-experiment conducted by Hofmann on 1 April 1976, with 2.0 mg of ergonovine maleate taken orally. Hofmann reported that this dose manifested a "slightly hallucinogenic activity" lasting more than five hours.2 [...] Our experiments corroborate Hofmann's report that ergonovine possesses entheogenic properties. We found the active dose to lie between 5.0 and 10.0 mg, peroral. It is interesting to note that Hofmann experienced distinct entheogenic effects at 2.0 mg, while Wasson and Ruck did not. Similarly, J.B. experienced distinct entheogenic effects at 3.0 mg, whereas J.O. and P.N. did not. This underscores the importance of metabolic individuality in the uptake and metabolism of mind-altering drugs. With respect to entheogenic effects 10 mg of ergonovine maleate is roughly equivalent to 50 μg is, ergonovine possesses about that LSD-tartrate, 1/200th the entheogenic potency of LSD.
Chemical transformations at N(6) were not accomplished until after clinical studies had been terminated. Initial work in this area was reported in 1970 by Fehr et al.184 who synthesized d-lysergic acid with various N(6) alkyl groups from 6-nor-d-lysergic acid methyl ester.151 Similar chemistry was first applied to LSD by Nakahara and Niwaguchi,185 then by Niwaguchi et al.,186 and most recently by Hoffman and Nichols.162 Initial pharmacological studies identified high activity in the isolated rat uterus preparation for the ethyl, propyl, and allyl analogues, from which high potency in the CNS was predicted.161
The ergolines can be viewed as rigid tetracyclic tryptamines. Within this class of compound is found the semisynthetic d-lysergic acid diethylamide (Fig 8) (d-LSD), the most potent of the hallucinogenic drugs. [...] Of the many structural modifications which have been made to the LSD structure, none had yielded a compound more potent than LSD itself. This report will briefly describe some derivatives of LSD which do appear to have somewhat higher potency than LSD. [...] The observations of potency comparable to, or greater than LSD [with N(6)-alkyl-substituted lysergamides] was of great interest. It seemed likely, based on the generalization in the drug discrimination assay and the high potencies of several of the derivatives, that these might well be more potent hallucinogens in man than LSD. Very recently, preliminary studies were carried out (A T Shulgin, personal communication) which indicated that indeed, the N(6)-ethyl and the N(6)-allyl-nor-LSD derivatives are somewhat more potent than LSD, by perhaps a factor of 2–3. Early results also indicated that N(6)-propyl-nor-LSD retains activity comparable to LSD, but with perhaps less visual distortion. These preliminary results were obtained after only a few experiments with each compound and further evaluation to define the potency and character of these lysergamides is underway.
EXAMPLE 38 Preparation of d-lysergic acid hexamethylene imide: [...]